NT5DC4

Model summary

A soluble human cytosolic phosphohydrolase that removes the 5′ phosphate from ribo- and deoxyribonucleotides, with a strong preference for purine substrates. By converting IMP, GMP, AMP, and dAMP into their corresponding nucleosides, it regulates nucleotide balance and feeds nucleoside salvage pathways. The enzyme operates through a metal-dependent mechanism typical of HAD hydrolases and likely self-associates to stabilize catalysis and tune specificity within cytosolic nucleotide-metabolism assemblies.

Predicted Gene Ontology terms

1. 01

   I begin with the InterPro architecture.

   The sequence is dominated by HAD superfamily signatures: IPR036412 (HAD-like superfamily, residues 2–412) blankets nearly the full length, while IPR023214 (HAD superfamily, residues 163–368) marks the catalytic core. Two family-level assignments, IPR016695 (Purine 5'-nucleotidase family, residues 3–393) and IPR008380 (HAD-superfamily hydrolase, subfamily IG, 5'-nucleotidase family, residues 4–399), specify both fold and chemistry. This ordered layout—an N-terminal to mid-region HAD scaffold with a central catalytic module and a C-terminal cap—defines a metal-dependent phosphohydrolase that hydrolyzes phosphate monoesters at the 5' position of ribo- and deoxyribonucleotides. The HAD catalytic core dictates a Mg2+-activated nucleophilic mechanism that releases inorganic phosphate and a nucleoside, and the subfamily IG annotation narrows the substrate class to 5'-nucleotidases that prefer purine monophosphates.

2. 02

   From this architecture, the molecular function resolves into two facets.

   First, the catalytic chemistry is unambiguous: GO:0008253 5'-nucleotidase activity arises from the HAD hydrolase mechanism and the purine-focused family signatures. Second, oligomerization is typical for HAD 5'-nucleotidases; cap-domain-mediated assembly frequently yields homodimers or higher-order assemblies. This structural propensity supports GO:0042802 identical protein binding, consistent with self-association that stabilizes the active-site geometry and modulates specificity.

3. 03

   The enzymatic role of removing 5' phosphates from nucleotides causally links to multiple metabolic pathways.

   By converting IMP and GMP to inosine and guanosine, and by acting on AMP and dAMP, the enzyme directly shapes GO:0046040 IMP metabolic process and GO:0046037 GMP metabolic process. Its capacity to hydrolyze AMP and dAMP places it in GO:0046059 AMP metabolic process and GO:0046065 dAMP metabolic process. Production of adenosine and inosine feeds into GO:0046085 adenosine metabolic process and GO:0046128 purine ribonucleoside metabolic process, while turnover of dAMP/dGMP-related streams contributes to GO:0009170 purine deoxyribonucleoside monophosphate metabolic process. Collectively, this network positions the enzyme as a cytosolic valve that balances nucleotide pools and supplies nucleosides for salvage.

4. 04

   Cellular location follows from the soluble HAD scaffold and absence of transmembrane or targeting signals.

   The enzyme’s soluble architecture and pathway context place it in the cytoplasm, specifically the GO:0005829 cytosol, where nucleotide interconversion and salvage are concentrated.

5. 05

   Mechanistically, the HAD core coordinates Mg2+ to activate a nucleophilic water that attacks the phosphate of 5'-ribonucleotides and 5'-deoxyribonucleotides, with cap-domain elements conferring purine preference and broadening substrate scope.

   I hypothesize that homodimerization (identical protein binding) tunes allostery and substrate channeling. In the cytosol, this enzyme likely forms transient assemblies with other nucleotide-metabolism factors—such as adenylate kinases and purine salvage enzymes—to buffer fluctuating purine pools. It may also associate with nucleoside transporters and glycosyltransferases that receive its products, creating a metabolon that couples hydrolysis to salvage and RNA/DNA precursor supply.